) announced that it has entered into a definitive agreement to
acquire privately-held biotechnology company, Seragon
The acquisition will provide Roche rights to Seragon's entire
portfolio of investigational next-generation oral selective
estrogen receptor degraders (SERDs) for the potential treatment of
hormone receptor-positive breast cancer.
As per the terms of the agreement, Roche, through its subsidiary
Genentech, will make an upfront cash payment of $725 million. The
agreement also includes milestone payments of up to $1 billion.
The transaction, subject to customary conditions, is expected to
close in the third quarter of 2014.
Once the transaction is completed, Seragon's portfolio will be
integrated into Genentech Research and Early Development.
We note that Seragon's lead candidate, ARN-810, is a
next-generation SERD that is currently in phase I. The trial is
being conducted among patients who have hormone receptor-positive
breast cancer and have failed current hormonal agents.
We remind investors that Roche is a leader in drugs for
oncology, immunology and infectious diseases.
In particular, Roche is a leader in breast cancer market with
its HER2 franchise with strong demand for drugs like Herceptin. The
HER2 franchise includes Herceptin, Perjeta and Kadcyla.
The acquisition will further strengthen Roche's pipeline.
Seragon's pipeline of next-generation SERDs will complement Roche's
existing research and development programs in breast cancer.
Roche currently carries a Zacks Rank #3 (Hold). Some
better-ranked stocks in the broader healthcare sector include
While Regeneron Pharma carries a Zacks Rank #1 (Strong Buy),
Shire and Allergan hold a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis
REGENERON PHARM (REGN): Free Stock Analysis
ALLERGAN INC (AGN): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis
To read this article on Zacks.com click here.